Date Published
April 2014 

Page Count 
103

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 



Vaccines: The End of Illness Table of Contents

Executive Summary 

Chapter 1: Introduction 

 1.1 The History of Vaccination

          1.1.1 Ancient

          1.1.2. 18th century

          1.1.3. 19th century

                   1.1.3.1. Pasteur

                   1.1.3.2. Coley’s toxins

          1.1.4. Mid 20th century 

1.2. Vaccines in the Doldrums: late 20th century

          1.2.1. Liability issues

          1.2.2. Vaccine denialism

1.3. The Current State of Vaccine technology, 2013

          1.3.1. WHO

1.3.2. Behemoth players: Bill and Melinda Gates

          1.3.3. Big pharma jumps in

 

Chapter 2: A Cornucopia of Vaccine Technologies 

2.1. Vaccine production: eggs versus cell culture

2.2. Cell line options

2.3 Conventional Vaccines

2.4. Adjuvants

2.5. Nanoparticle-based vaccines

2.6. DNA Vaccines

2.7. Vaccines driving T-cell activation

2.8. Dendritic cells

 

Chapter 3: Vaccine Targets 

3.1. Infectious Diseases

3.1.1. Influenza

3.1.2. HSV A & B

3.1.3. C. difficile 

3.1.4. HIV

3.1.5. Pneumococcus

3.1.6. Typhoid

3.1.7. Candida

3.1.8. Rabies

3.1.9. Rotavirus

3.1.10. Polio

3.1.11. Malaria

3.1.12. Parasitic diseases

3.1.13. Smallpox

3.1.14. Cholera

3.1.15. Mumps

3.1.16. Diphtheria

3.2. Cancer vaccines

          3.2.1. Human papilloma virus

          3.2.2. Breast cancer

          3.2.3. Pancreatic cancer

          3.2.4. Renal cell carcinoma

          3.2.5. Melanoma: dendritic cells

          3.2.6. Prostate cancer

 

Chapter 4: Big Pharma Vaccines 

4.1. AstraZeneca (Medimmune)

4.2. Baxter

4.3. GSK

4.4. J&J (Crucel)

4.5. Merck

4.6. Novartis

4.7. Pfizer

4.8. Sanofi

 

Chapter 5: Small Pharma Vaccines 

5.1. AC Immune

5.2. Aeras

5.3. Alphavax

5.4. Astrellas

5.6. Bavarian Nordic

5.7. BiondVax Pharmaceuticals

5.8. Braasch Biotech LLC    

5.9. Celldex

5.10. Chrontech

5.11. Emergent Biosolutions

5.12. EpiVax

5.13. GenVec

5.14. GeoVax

5.15. Genocea Biosciences

5.16. Immune Targeting Systems

5.17. Indian Immunologicals Limited

5.18. Inovio

5.19. Inviragen

5.20. Juvaris Biotherapeutics

5.21. Medicago

5.22. Mymetics

5.23. NovaRx

5.24. Novavax

5.25. Nuron

5.26. OPKO

5.27. Profectus Bioscience Inc

5.28. Sinovac                                                    

5.29. Sorrento Therapeutics, Inc.

5.30. TapImmune

5.31. Valneva

5.32. VaxInnate

5.33. VaxLiant

5.34. VBI vaccines

5.35. Vical

 

Chapter 6: Regulatory Issues 

6.1. A bumpy road

6.2. Current regulatory status

 

Chapter 7:The Future of Vaccine technology 

7.1. Challenges in delivery and storage

7.2. Dry vaccine technology: Ready for prime time?

7.3. A universal Vaccine                         

7.4. Outlandish targets

          7.4.1. Drug abuse

          7.4.2. Obesity

          7.4.3. Smoking

          7.4.4. Alcoholism

7.4.5. Alzheimer’s disease

          7.4.6. Parkinson’s Disease

7.5. Bioterrorism: A global threat?

7.6. Intellectual Property in the Balance

7.7. A bright future for Vaccines

  

Chapter 8: Survey of Opinion Concerning Vaccine technology by Members of the Industry